Q: Why are CJC-1295 and Ipamorelin paired together?
A: They influence growth hormone release through different signaling pathways. CJC-1295 acts through GHRH receptors, while ipamorelin activates the ghrelin receptor. Combining them does not, however, establish that the treatment will produce a particular clinical outcome.
Q: Is this the same as taking human growth hormone (HGH)?
A: No. CJC-1295 and ipamorelin are not HGH. They interact with signaling pathways involved in stimulating endogenous growth hormone release.
Q: What is the difference between CJC-1295 with and without DAC?
A: The drug affinity complex (DAC) affects how long it remains active in the body. Because these are distinct formulations, the exact form dispensed should be confirmed before establishing a treatment protocol.
Q: Do they increase IGF-1?
A: Growth hormone signaling can influence downstream IGF-1 production. The degree of response varies, which is one reason our healthcare provider may consider clinical and laboratory monitoring when appropriate.
Q: Can this combination be used for fat loss or muscle growth?
A: CJC-1295 and ipamorelin are frequently discussed in connection with body composition, but adequate clinical evidence has not established this compounded combination as a treatment for fat loss or muscle gain. Those outcomes should not be assumed or guaranteed.
Q: Are there safety considerations?
A: Yes. Human safety information for these peptides and this combination is limited. FDA has identified potential safety concerns associated with compounded CJC-1295 and ipamorelin, including concerns related to immunogenicity, peptide impurities, and limited safety data. Our healthcare provider should review potential risks before treatment is considered.
